New Risk • May 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.0m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (AU$14.0m market cap, or US$9.98m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$11m net loss in 2 years). Shareholders have been diluted in the past year (15% increase in shares outstanding). New Risk • May 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$11m net loss in 2 years). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (AU$18.7m market cap, or US$13.5m). Major Estimate Revision • May 11
Consensus EPS estimates upgraded to AU$0.0084 loss, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from AU$16.5m to AU$15.4m. 2026 losses expected to reduce from -AU$0.0107 to -AU$0.0084 per share. Medical Equipment industry in Australia expected to see average net income growth of 27% next year. Consensus price target down from AU$0.048 to AU$0.036. Share price fell 22% to AU$0.007 over the past week. New Risk • Apr 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$16m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$12m net loss in 2 years). Market cap is less than US$100m (AU$28.5m market cap, or US$20.5m). New Risk • Mar 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$16m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$13m net loss in 2 years). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (AU$34.7m market cap, or US$24.7m). Major Estimate Revision • Feb 28
Consensus EPS estimates fall by 17% The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -AU$0.0091 to -AU$0.0107 per share. Revenue forecast unchanged at AU$17.4m. Medical Equipment industry in Australia expected to see average net income growth of 43% next year. Consensus price target down from AU$0.081 to AU$0.065. Share price was steady at AU$0.017 over the past week. New Risk • Feb 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$7.8m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$30.6m market cap, or US$21.5m). New Risk • Jan 29
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$23m Forecast net loss in 3 years: AU$10m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$10m net loss in 3 years). Market cap is less than US$100m (AU$65.2m market cap, or US$45.9m). Breakeven Date Change • Jan 29
No longer forecast to breakeven The 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$6.55m in 2028. New consensus forecast suggests the company will make a loss of AU$433.3k in 2028. Announcement • Jan 27
ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026 ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026 Price Target Changed • Dec 11
Price target decreased by 11% to AU$0.098 Down from AU$0.11, the current price target is an average from 4 analysts. New target price is 164% above last closing price of AU$0.037. Stock is down 34% over the past year. The company is forecast to post a net loss per share of AU$0.0086 next year compared to a net loss per share of AU$0.012 last year. Major Estimate Revision • Dec 02
Consensus revenue estimates increase by 12% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from AU$16.7m to AU$18.7m. Forecast losses expected to reduce from -AU$0.0085 to -AU$0.0075 per share. Medical Equipment industry in Australia expected to see average net income growth of 41% next year. Consensus price target of AU$0.11 unchanged from last update. Share price was steady at AU$0.036 over the past week. Breakeven Date Change • Nov 08
No longer forecast to breakeven The 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$6.55m in 2028. New consensus forecast suggests the company will make a loss of AU$10.5m in 2028. New Risk • Nov 06
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: AU$23m Forecast net loss in 2 years: AU$1.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$1.3m net loss in 2 years). Market cap is less than US$100m (AU$75.3m market cap, or US$49.0m). Announcement • Oct 24
ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025 ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025 Announcement • Sep 19
ImpediMed Limited, Annual General Meeting, Nov 18, 2025 ImpediMed Limited, Annual General Meeting, Nov 18, 2025. Major Estimate Revision • Sep 03
Consensus EPS estimates fall by 19% The consensus outlook for fiscal year 2026 has been updated. 2026 losses of -AU$0.007 per share expected, vs -AU$0.0059 per share profit forecast previously. Revenue forecast reaffirmed at AU$20.6m. Medical Equipment industry in Australia expected to see average net income growth of 32% next year. Consensus price target down from AU$0.15 to AU$0.11. Share price fell 9.3% to AU$0.039 over the past week. Price Target Changed • Aug 30
Price target decreased by 25% to AU$0.11 Down from AU$0.15, the current price target is an average from 3 analysts. New target price is 182% above last closing price of AU$0.039. Stock is down 19% over the past year. The company is forecast to post a net loss per share of AU$0.007 next year compared to a net loss per share of AU$0.012 last year. Reported Earnings • Aug 29
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in FY 2024). Revenue: AU$12.7m (up 23% from FY 2024). Net loss: AU$23.2m (loss widened 17% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 02
No longer forecast to breakeven The 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.04m in 2027. New consensus forecast suggests the company will make a loss of AU$2.53m in 2027. Announcement • Jul 16
ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025 ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025 New Risk • Jul 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$991k net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$79.0m market cap, or US$52.0m). Breakeven Date Change • May 07
Forecast to breakeven in 2027 The 3 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 40% per year to 2026. The company is expected to make a profit of AU$5.04m in 2027. Average annual earnings growth of 84% is required to achieve expected profit on schedule. Announcement • Apr 17
ImpediMed Limited to Report Q3, 2025 Results on Apr 30, 2025 ImpediMed Limited announced that they will report Q3, 2025 results on Apr 30, 2025 Price Target Changed • Mar 11
Price target increased by 8.8% to AU$0.15 Up from AU$0.14, the current price target is an average from 3 analysts. New target price is 256% above last closing price of AU$0.042. Stock is down 62% over the past year. The company is forecast to post a net loss per share of AU$0.0076 next year compared to a net loss per share of AU$0.0098 last year. Reported Earnings • Mar 01
First half 2025 earnings released: EPS: AU$0 (vs AU$0 in 1H 2024) First half 2025 results: EPS: AU$0 (in line with 1H 2024). Revenue: AU$6.01m (up 26% from 1H 2024). Net loss: AU$11.1m (loss widened 15% from 1H 2024). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Breakeven Date Change • Feb 27
No longer forecast to breakeven The 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$7.41m in 2027. New consensus forecast suggests the company will make a loss of AU$89.1k in 2027. Breakeven Date Change • Jan 31
No longer forecast to breakeven The 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$10.4m in 2027. New consensus forecast suggests the company will make a loss of AU$89.1k in 2027. Announcement • Jan 28
ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025 ImpediMed Limited announced that they will report Q2, 2025 results on Jan 31, 2025 Recent Insider Transactions • Nov 29
Non-Executive Director recently bought AU$76k worth of stock On the 20th of November, Fiona Bones bought around 920k shares on-market at roughly AU$0.083 per share. This transaction increased Fiona's direct individual holding by 12x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$639k more in shares than they have sold in the last 12 months. Announcement • Oct 15
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 ImpediMed Limited announced that they will report Q1, 2025 results on Oct 22, 2024 Announcement • Sep 27
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 ImpediMed Limited, Annual General Meeting, Nov 19, 2024. Price Target Changed • Sep 09
Price target decreased by 8.8% to AU$0.15 Down from AU$0.17, the current price target is an average from 4 analysts. New target price is 231% above last closing price of AU$0.046. Stock is down 72% over the past year. The company is forecast to post a net loss per share of AU$0.0061 next year compared to a net loss per share of AU$0.0098 last year. Major Estimate Revision • Sep 04
Consensus revenue estimates decrease by 14% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from AU$18.6m to AU$16.0m. EPS estimate unchanged from -AU$0.0061 per share at last update. Medical Equipment industry in Australia expected to see average net income growth of 33% next year. Consensus price target broadly unchanged at AU$0.16. Share price fell 11% to AU$0.048 over the past week. Recent Insider Transactions • Sep 03
Board Member recently bought AU$73k worth of stock On the 30th of August, Andrew Grant bought around 1m shares on-market at roughly AU$0.073 per share. This transaction increased Andrew's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$544k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 30
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: AU$0 (improved from AU$0.011 loss in FY 2023). Revenue: AU$10.3m (down 9.0% from FY 2023). Net loss: AU$19.8m (loss narrowed 3.6% from FY 2023). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 29
Forecast to breakeven in 2027 The 2 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$23.7m in 2027. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Announcement • Aug 23
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 ImpediMed Limited announced that they will report fiscal year 2024 results Pre-Market on Aug 29, 2024 Breakeven Date Change • Jul 30
Forecast to breakeven in 2026 The 4 analysts covering ImpediMed expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 16% per year to 2025. The company is expected to make a profit of AU$1.95m in 2026. Average annual earnings growth of 54% is required to achieve expected profit on schedule. Announcement • Jun 08
ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director The Board of ImpediMed Limited announced the appointment of Ms Fiona Bones as a non-Executive Director of the Company, effective 07 June 2024. Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones is a Fellow of the Association of Chartered Certified Accountants, UK and Ireland and brings global experience in finance, corporate governance, and systems transformation. New Risk • Jun 04
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$149.7m (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$8.1m net loss in 2 years). Market cap is less than US$100m (AU$149.7m market cap, or US$99.4m). Recent Insider Transactions • May 15
Independent Non-Executive Director recently bought AU$50k worth of stock On the 8th of May, Janelle Delaney bought around 634k shares on-market at roughly AU$0.079 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$100k. Insiders have collectively bought AU$883k more in shares than they have sold in the last 12 months. Announcement • Apr 20
ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024 ImpediMed Limited announced that they will report Q3, 2024 results on Apr 30, 2024 Price Target Changed • Apr 16
Price target decreased by 9.6% to AU$0.18 Down from AU$0.19, the current price target is an average from 4 analysts. New target price is 87% above last closing price of AU$0.094. Stock is down 15% over the past year. The company is forecast to post a net loss per share of AU$0.0095 next year compared to a net loss per share of AU$0.011 last year. Announcement • Apr 11
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting ImpediMed announced that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on April 12, 2024. The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period. The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure. Lymphedema, a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk. ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with US payors now providing coverage for over 140 million covered lives. The PREVENT trial is a pivotal study and the largest randomized controlled trial to assess lymphedema prevention. The study enrolled 1,200 patients across 10 trial sites in the US and Australia, involving 13 hospitals, including Vanderbilt University, Mayo Clinic and MD Anderson. The trial was conducted over six and a half years and patients were followed for up to three years, with the primary aim to determine if early intervention in patients with subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy results in a lower rate of lymphedema progression versus the rate when tape measure is used for subclinical detection. The manuscript is published in Lymphatic Research and Biology. The results of the trial demonstrated that patients with early detection with L-Dex™ technology and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years. Recent Insider Transactions • Mar 28
Independent Non-Executive Director recently bought AU$100k worth of stock On the 25th of March, Janelle Delaney bought around 1m shares on-market at roughly AU$0.087 per share. This transaction amounted to 54% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$905k more in shares than they have sold in the last 12 months. Major Estimate Revision • Mar 04
Consensus revenue estimates decrease by 13% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from AU$13.4m to AU$11.7m. EPS estimate unchanged from -AU$0.0093 per share at last update. Medical Equipment industry in Australia expected to see average net income growth of 19% next year. Consensus price target down from AU$0.19 to AU$0.18. Share price rose 4.7% to AU$0.09 over the past week. Recent Insider Transactions • Mar 02
Independent Non-Executive Director recently bought AU$90k worth of stock On the 29th of February, Andrew Grant bought around 230k shares on-market at roughly AU$0.39 per share. This transaction increased Andrew's direct individual holding by 3x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth AU$135k. Insiders have collectively bought AU$898k more in shares than they have sold in the last 12 months. Price Target Changed • Feb 03
Price target decreased by 12% to AU$0.19 Down from AU$0.22, the current price target is an average from 3 analysts. New target price is 103% above last closing price of AU$0.096. Stock is up 66% over the past year. The company is forecast to post a net loss per share of AU$0.0093 next year compared to a net loss per share of AU$0.011 last year. Breakeven Date Change • Feb 03
No longer forecast to breakeven The 3 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.15m in 2026. New consensus forecast suggests the company will make a loss of AU$2.18m in 2026. Board Change • Feb 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Janelle Delaney is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. New Risk • Jan 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Announcement • Jan 23
ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024 ImpediMed Limited announced that they will report first half, 2024 results on Feb 27, 2024 Recent Insider Transactions • Dec 19
Independent Non-Executive Director recently bought AU$135k worth of stock On the 14th of December, Janelle Delaney bought around 942k shares on-market at roughly AU$0.14 per share. This transaction increased Janelle's direct individual holding by 14x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$814k more in shares than they have sold in the last 12 months. Major Estimate Revision • Nov 21
Consensus revenue estimates decrease by 20% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from AU$16.8m to AU$13.4m. EPS estimate unchanged from -AU$0.0085 per share at last update. Medical Equipment industry in Australia expected to see average net income growth of 0.4% next year. Consensus price target down from AU$0.23 to AU$0.22. Share price fell 3.7% to AU$0.13 over the past week. Price Target Changed • Nov 10
Price target decreased by 16% to AU$0.23 Down from AU$0.27, the current price target is an average from 3 analysts. New target price is 70% above last closing price of AU$0.14. Stock is up 42% over the past year. The company is forecast to post a net loss per share of AU$0.0085 next year compared to a net loss per share of AU$0.011 last year. Price Target Changed • Nov 01
Price target increased by 21% to AU$0.27 Up from AU$0.23, the current price target is an average from 3 analysts. New target price is 160% above last closing price of AU$0.10. Stock is up 15% over the past year. The company is forecast to post a net loss per share of AU$0.0078 next year compared to a net loss per share of AU$0.011 last year. Announcement • Oct 24
ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023 ImpediMed Limited announced that they will report Q1, 2024 results on Oct 31, 2023 Announcement • Oct 12
ImpediMed Limited, Annual General Meeting, Nov 30, 2023 ImpediMed Limited, Annual General Meeting, Nov 30, 2023, at 10:01 E. Australia Standard Time. Board Change • Oct 05
High number of new directors There are 8 new directors who have joined the board in the last 3 years. Director McGregor Grant was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Sep 27
ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer ImpediMed Limited announced the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023. Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry. Dr. Chen's previous leadership and experience: Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care. Chief of Breast Surgery, University of California Davis Medical Center. Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California. Past President, American Society of Breast Surgeons (ASBrS). Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics. Over 70 publications and 5,000 citations. The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®). Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons. Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business. Major Estimate Revision • Sep 06
Consensus revenue estimates decrease by 23% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from AU$21.7m to AU$16.8m. EPS estimate unchanged from -AU$0.006 per share at last update. Medical Equipment industry in Australia expected to see average net income growth of 1.1% next year. Consensus price target down from AU$0.24 to AU$0.23. Share price fell 5.7% to AU$0.17 over the past week. Reported Earnings • Aug 31
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: AU$0.01 loss per share. Revenue: AU$11.3m (up 7.4% from FY 2022). Net loss: AU$20.5m (loss widened 3.3% from FY 2022). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Reported Earnings • Aug 31
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: AU$0.01 loss per share. Revenue: AU$11.3m (up 7.4% from FY 2022). Net loss: AU$20.5m (loss widened 3.3% from FY 2022). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Announcement • Aug 18
ImpediMed Limited, Annual General Meeting, Sep 28, 2023 ImpediMed Limited, Annual General Meeting, Sep 28, 2023, at 09:00 E. Australia Standard Time. Location: Sydney offices of Johnson Winter Slattery at Quay Quarter Tower, Level 14, 50 Bridge Street Sydney Nsw 2000 Australia Agenda: To consider and removal of Four existing Directors of the company; and to consider and appointment of Four new Directors. Price Target Changed • Jul 21
Price target increased by 27% to AU$0.21 Up from AU$0.17, the current price target is an average from 4 analysts. New target price is 5.3% above last closing price of AU$0.20. Stock is up 264% over the past year. The company is forecast to post a net loss per share of AU$0.0082 next year compared to a net loss per share of AU$0.012 last year. Announcement • Jul 17
ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023 ImpediMed Limited announced that they will report Q4, 2023 results on Jul 24, 2023 Announcement • Jul 06
ImpediMed Limited Appoints Daniel Sharp as Director ImpediMed Limited appointed Mr. Daniel Sharp as director, date of appointment is July 1, 2023. Recent Insider Transactions • Jun 28
Executive Director recently bought AU$144k worth of stock On the 20th of June, David Anderson bought around 920k shares on-market at roughly AU$0.16 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth AU$158k. Insiders have collectively bought AU$1.0m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Jun 14
Independent Non-Executive Chairman recently bought AU$82k worth of stock On the 6th of June, Donald Williams bought around 500k shares on-market at roughly AU$0.16 per share. This transaction amounted to 7.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Donald has been a buyer over the last 12 months, purchasing a net total of AU$273k worth in shares. Breakeven Date Change • May 30
No longer forecast to breakeven The 4 analysts covering ImpediMed no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$891.8k in 2025. New consensus forecast suggests the company will make a loss of AU$377.6k in 2025. Recent Insider Transactions • Apr 22
MD, CEO & Director recently bought AU$52k worth of stock On the 20th of April, Richard Valencia bought around 410k shares on-market at roughly AU$0.13 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$64k. Richard has been a buyer over the last 12 months, purchasing a net total of AU$170k worth in shares. Recent Insider Transactions • Mar 31
MD, CEO & Director recently bought AU$54k worth of stock On the 27th of March, Richard Valencia bought around 400k shares on-market at roughly AU$0.13 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$64k. Richard has been a buyer over the last 12 months, purchasing a net total of AU$118k worth in shares. Price Target Changed • Mar 29
Price target increased by 25% to AU$0.18 Up from AU$0.15, the current price target is an average from 3 analysts. New target price is 75% above last closing price of AU$0.10. Stock is down 28% over the past year. The company is forecast to post a net loss per share of AU$0.0094 next year compared to a net loss per share of AU$0.012 last year. Recent Insider Transactions • Mar 08
MD, CEO & Director recently bought AU$64k worth of stock On the 6th of March, Richard Valencia bought around 1m shares on-market at roughly AU$0.064 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months. Reported Earnings • Feb 25
First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022) First half 2023 results: AU$0.01 loss per share (further deteriorated from AU$0.006 loss in 1H 2022). Revenue: AU$5.66m (up 8.8% from 1H 2022). Net loss: AU$10.8m (loss widened 21% from 1H 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Price Target Changed • Jan 31
Price target decreased by 7.7% to AU$0.17 Down from AU$0.18, the current price target is an average from 4 analysts. New target price is 180% above last closing price of AU$0.059. Stock is down 69% over the past year. The company is forecast to post a net loss per share of AU$0.0087 next year compared to a net loss per share of AU$0.012 last year. Announcement • Jan 24
ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023 ImpediMed Limited announced that they will report Q2, 2023 results on Jan 30, 2023 
